NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
November 15, 2023 16:05 ET
|
NextCure
New publication in Journal of Clinical Investigation provides compelling evidence for NC525’s ability to specifically kill leukemic cells while sparing healthy cells in non-clinical modelingUpdate for...
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
November 02, 2023 16:05 ET
|
NextCure
Phase 1b updates for NC410 and NC762, and operational update for NC525 Phase 1a are expected by year endCash of approximately $118 million expected to fund operations into mid-2025 BELTSVILLE, Md.,...
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
October 17, 2023 08:05 ET
|
NextCure
BELTSVILLE, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
September 26, 2023 16:05 ET
|
NextCure
Data presented at the 2023 Cambridge Health Tech Institute's 2nd Annual Neurodegeneration Targets Conference in Boston, MAIn preclinical testing, NC181 demonstrated amyloid clearance, prevention of...
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
September 12, 2023 08:05 ET
|
NextCure
• Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore BELTSVILLE, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- ...
NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
September 07, 2023 16:05 ET
|
NextCure
BELTSVILLE, Md., Sept. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease
September 05, 2023 16:05 ET
|
NextCure
Data Presented at the 2023 Military Health System Research Symposium show activity in animal model of acute spinal cord injury-induced immobilization BELTSVILLE, Md., Sept. 05, 2023 (GLOBE...
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023 07:00 ET
|
NextCure
BELTSVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
August 03, 2023 16:05 ET
|
NextCure
Phase 1b data for NC410 and further updates on other clinical programs expected in the fourth quarter of 2023Cash of approximately $131 million expected to fund operations into mid-2025 BELTSVILLE,...
NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
June 21, 2023 16:05 ET
|
NextCure
BELTSVILLE, Md., June 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...